Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC)

被引：22

作者：

Belani, C. P.

Waterhouse, D. M.

Ghazal, H.

Ramalingam, S. S.

Bordoni, R.

Greenberg, R.

Levine, R. M.

Waples, J. M.

Jiang, Y.

Reznikoff, G.

机构：

[1] Penn State Hershey Canc Inst, Hershey, PA USA

[2] Oncol Hematol Care Inc, Cincinnati, OH USA

[3] Kentucky Canc Clin, Hazard, KY USA

[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[5] Georgia Canc Specialists PC, Marietta, GA USA

[6] Ctr Canc & Hematol Dis, Cherry Hill, NJ, Albania

[7] Space Coast Med Associates, Titusville, FL USA

[8] Clearview Canc Inst, Huntsville, AL USA

[9] Med Specialists Fairfield, Fairfield, CT USA

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.7506

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7506

引用

页数：1